Skip to main content

Table 1 Characteristics of studies included in this systematic review

From: Assessment of the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis patients: a systematic review and meta-analysis on clinical trials

Studies Study design Location/setting No. patients (intervention/control) Age, years (intervention/control) Treatment of intervention group Treatment of control group Follow-up, months
Li [10] Open-label RCT Hong Kong/single center 30/30 58.0/59.1 Ramipril 5 mg/day Conventional antihypertensive therapy except for ACEI or ARB or both 12
Phakdeekitcharoen [16] Open-label cross-over RCT Thailand/single center 29 44.8 Group 1:
Enalapril 10 mg/day
Group 2:
Candesartan 8 mg/day
Group 1:
Candesartan 8 mg/day
Group 2:
Enalapril 10 mg/day
4
Reyes-Marín [20] Parallel RCT Mexico/single center 30/30 42.5/49.2 Group 1:
Enalapril 10 mg/day
Group 2:
Losartan 50 mg/day
12
Suzuki [11] Double-blind RCT Japan/single center 14/10 56/57 Valsartan 40~80 mg/day Conventional antihypertensive therapy 12
Suzuki [15] Open-label RCT Japan/single center 18/16 63.5/63.5 Valsartan 40~80 mg/day Conventional antihypertensive therapy except for ACEI or ARB or both 24
Shigenaga [19] Open-label RCT Japan/single center 15/15 52.9/53.3 Group 1:
Candesartan l~4 mg/day
Group 2:
Valsartan ~ 40 mg/day
Conventional antihypertensive therapy except for ACEI or ARB or both 6
Zhong [18] Open-label RCT China/single center 24/20 44 Irbesartan 300 mg/day Conventional antihypertensive therapy except for ACEI or ARB or both 12
Wang [17] Open-label RCT China/single center 19/13 42 Valsartan 80 mg/day Conventional antihypertensive therapy except for ACEI or ARB or both 28
  1. Abbreviations: RCT randomized controlled trial, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker